Financial
FY2026 revenue A$51.6m (+27.0%); net margin 4.5%; net income A$2.3m.
Underlying EBITDA A$6.8m (+34%); A$20.6m cash, no debt.
Alcidion
HQ Australia · Asia-Pacific
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Fair
Customer rating
No reviews yet
Financial health
Band: FairListed: ALC.AX
FY2026 revenue A$51.6m (+27.0%); net margin 4.5%; net income A$2.3m.
Underlying EBITDA A$6.8m (+34%); A$20.6m cash, no debt.
Source: official results release · Year ended 2026-06-30 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2026 | A$51.6m | +27.0% | — | A$2.3m | Alcidion Group |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
No adverse media involving Alcidion found in HSH's search of the last 24 months.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Alcidion found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Clinical software supplier (Miya Precision); no regulatory or clinical safety actions involving Alcidion found in HSH's search of the last 24 months.
Contract performance
May 2026: North Cumbria Integrated Care went live with Alcidion's Miya Precision EPR after NHS England held back the planned March go-live; the trust said it had no significant local concerns. Jan 2026: University Hospitals Sussex selected Alcidion as EPR supplier.
Competitors
No competitors linked yet.